Light-Controlled Immunotherapy

Brief Description

A novel therapy using light-activated chemokine receptors to direct specific lymphocytes to desired locations within a patient's body.

Problem Solved by the Technology

Most current cancer treatments are delivered systemically,and are usually associated with undesirable side-effects, including nausea, hair loss, and weakness.

Applications

Dr. Minsoo Kim at the University of Rochester has engineered the means to direct ex vivo-generated immune-promoting or tolerogenic T cells either to enhance immunity or to promote adoptive cell transfer therapies in patients. By applying this methodology to tumor-targeting cytotoxic T cells, Dr. Kim has been able to achieve a significant reduction in tumor growth in mouse models. Clinically, this photoactivatable chemokine receptor approach may have broad applications for adoptive cell transfer therapy.

Publications

Xu Y et al. Optogenetic Control of Chemokine Receptor Signal and T-cell Migration. PNAS. 2014 Apr 29; 111(17):6371-6.

Intellectual Property Status

Patent applications pending in United States, Australia, Canada, and Europe.

URV Reference Number: 6-1995

Patent Information:
Category(s):
Therapeutic
For Information, Contact:
Matan Rapoport
Licensing Associate
University of Rochester
585.276.6600
matan.rapoport@rochester.edu
Inventors:
Minsoo Kim
Keywords:
Anti-inflammatory
Autoimmune